| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,664,127 | 6,480,930 | ||
| Prepaid expenses and other current assets | 407,283 | 159,586 | ||
| Total assets | 5,071,410 | 6,640,516 | ||
| Accounts payable (including related party amounts of 185,300 and 0, respectively) | 453,427 | 413,687 | ||
| Accrued and other current liabilities (including related party amounts of 28,600 and 0, respectively) | 657,881 | 612,578 | ||
| Total liabilities | 1,111,308 | 1,026,265 | ||
| Common stock, par value 0.0001 per share, 250,000,000 shares authorized 844,457 shares issued and outstanding as of september 30, 2025 251,725 shares issued and outstanding as of december 31, 2024 | 84 | 64 | ||
| Additional paid-in capital | 75,332,026 | 75,294,206 | ||
| Accumulated deficit | -71,372,008 | -69,680,019 | ||
| Total stockholders equity | 3,960,102 | 5,614,251 | ||
| Total liabilities and stockholders equity | 5,071,410 | 6,640,516 | ||
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)